Defense Medicine

The company believes Defense Medicine™ solutions represent an area with significant growth potential not only in developing innovative treatments for battlefield injuries using our proprietary technology and intellectual property, but also in translating those treatments into commercial uses.

In 2009, Oxygen Biotherapeutics, Inc. formed the Purple Heart Injury Laboratories (PHIL) as a not-for-profit research institution to develop new treatments for battlefield injuries. The goal for PHIL is to assure rapid development of life-saving technologies and therapies for the U.S. Warfighter. The company will have the exclusive rights to translate those technologies to commercial uses for the civilian population.

Visit the PHIL website